NP41422 Contraceptive Medicines
The value below is a framework or dynamic market ceiling: the maximum
that could be spent across all call-offs, not the value of a single contract.
Aggregate figures on this site exclude these to avoid double counting.
key details
| Status | complete |
|---|---|
| Category (CPV) | 33600000 +2 more |
| Region | Scotland |
| Procedure | open |
| OCID | ocds-h6vhtk-037d80 |
Awards (7)
This procurement was awarded to 7 suppliers. Values shown are per-award; the notice total is ·.
| Supplier | Value | Date | Status |
|---|---|---|---|
| Bayer Plc shared | · | · | active |
| Consilient Health Ltd shared | · | · | · |
| Gedeon Richter shared | · | · | · |
| Morningside Pharmaceuticals Limited shared | · | · | · |
| Organon Pharma (UK) Ltd. shared | · | · | active |
| Pfizer Ltd shared | · | · | · |
| Zentiva Pharma UK Ltd shared | · | · | · |
description
This Framework Agreement is for the supply of Contraceptive Medicines to health boards across NHS Scotland. Full details are contained in section II.2 of this notice.
documents
- NP41422 Contraceptive Medicines , contractNotice
- NP41422 Contraceptive Medicines , awardNotice
Documents are linked, not mirrored. They are served by the publishing authority and may require registration.
notice history
3 notices published against this procurement.
| Published | Type | Regime | Notice |
|---|---|---|---|
| 8 Jul 2022 | Contract notice (F02) | Earlier regulations | 018695-2022 |
| 13 Jul 2022 | Corrigendum (F14) | Earlier regulations | 019119-2022 |
| 31 Oct 2022 | Contract award notice (F03) | Earlier regulations | 030599-2022 |
more from The Common Services Agency (more commonly known as NHS National Services Scotland) ("the Authority")
- NP40925 Analgesics, Anaesthetics, Musculoskeletal & Joint Disease Medicines · £22,471,323 · 6 Jan 2026
- Contrast Media Agents · £44,036,295 · 27 Jun 2024
- NP40923 Analgesics, Anaesthetics, Musculoskeletal & Joint Disease Medicines · £35,467,873 · 7 Mar 2024
- NP811-17 Lift Maintenance Services · £5,750,000 · 19 Jul 2023
- Generic and Biosimilar Cancer Medicines · £33,350,281 · 21 Apr 2023
- NP36722 Fertility Products · £6,490,616 · 18 Jan 2023
- NP39722f Lenalidomide · £4,300,000 · 7 Jun 2022
- Generic Medicines Transition Tender · £1,798,519 · 20 May 2022
all contracts from this buyer →
similar contracts awarded
Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.
- Radiopharmaceutical Products - Poltech · The Christie NHS Foundation Trust · £39,000
- NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026 · NHS England · £592,363,416
- NHS National Generics Pharmaceuticals - Supply Chain Resilience · NHS England · £52,447,296
- Generic, Branded Generic & Proprietary Medicinal Products - Group 18 · Regional Business Services Organisation, Procurement and Logistics Service · £1,800,000,000
- Generic Drugs – Injections/Infusions 2 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £6,535,850
- Transitional Drugs 7 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £53,566,932
- NP90726m Vedolizumab (Entyvio®) · The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland) · £47,898,609
- Combined Needles and Syringes Lot 1 · Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency · £15,264,000
source
Published on Find a Tender. Contact details for named individuals are not reproduced on this site.